Certara expands PBPK simulator availability

By Melissa Fassbender

- Last updated on GMT

Certara expands PBPK simulator availability

Related tags Pharmacokinetics Pharmacology

Certara has developed a new licensing approach, which provides smaller organizations access to its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform.

According to the company, Simcyp Access represents a new cloud-based licensing approach for pharmaceutical companies with less than 500 employees.

As Outsorucing-Pharma.com previously reported​, Simcyp helps predict pharmacokinetic outcomes in virtual patient populations.

The most recent version​ of the simulator includes enhanced lung, pediatric, and GI transit models, as well as a new dermal absorption model, and a new report assistant.

In order to access the simulator on a rental basis, users must be previously trained on the platform.

Certara explained employees are considered trained if they have attended a Simcyp Workshop within the past three years.

(Feature image: iStock/Torsakarin)

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars